Skip to main content

Clinical Trials Using Elranatamab

Review the clinical trials studying elranatamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-15 of 15

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Status: Active
Location: 7 locations
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Status: Active
Location: 6 locations
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Status: Active
Location: 6 locations
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Status: Active
Location: 5 locations
Elranatamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Who Have Received Idecabtagene Vicleucel
Status: Active
Location: 3 locations
Elranatamab for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis
Status: Active
Location: 2 locations
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Elranatamab as Maintenance Therapy after Ciltacabtagene-Autoleucel for the Treatment of High Risk Relapsed Refractory Multiple Myeloma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Therapy in Patents with Newly Diagnosed Multiple Myeloma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
MRD-Adapted Elranatamab for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Elranatamab and Isatuximab for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Elranatamab, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Pre-Transplant Purging and Post-Transplant MRD-Guided Maintenance Therapy with Elranatamab in Patients with High-Risk Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Vaccine (DC/MM Fusion) in Combination with Elranatamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 2 locations
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin